UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
March 14, 2017
Date of report (Date of earliest event reported)
Axsome Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
Delaware | | 001-37635 | | 45-4241907 |
(State or other jurisdiction | | (Commission | | (IRS Employer |
of incorporation) | | File Number) | | Identification No.) |
25 Broadway, 9th Floor | | |
New York, New York | | 10004 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code (212) 332-3241
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events
On March 14, 2017, Axsome Therapeutics, Inc. (the “Company”) updated its presentation slide deck in preparation for a presentation by Herriot Tabuteau, M.D., Chief Executive Officer of the Company, at the 29th Annual ROTH Conference (the “Conference”) on March 14, 2017. Dr. Tabuteau will be presenting at the Conference to provide an overview of the Company’s business and late-stage clinical product candidates, AXS-05 and AXS-02. Attached as Exhibit 99.1 to this Current Report on Form 8-K is a copy of the presentation slide deck to be used in connection with this presentation.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit | | |
Number | | Description |
99.1 | | Corporate Presentation |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Axsome Therapeutics, Inc. |
| |
| |
Dated: March 14, 2017 | By: | /s/ Herriot Tabuteau, M.D. |
| Name: Herriot Tabuteau, M.D. |
| Title: Chief Executive Officer |
3
